Please assess the completion status of the following clinical trial:

Trial Title: Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Verified allergic sensitivity to either Timothy Grass or Short Ragweed pollen (primary allergen)~* Verified allergic sensitivity to at least one allergen in addition to the primary allergen~Exclusion Criteria:~* Negative skin testing to Timothy Grass or Short Ragweed pollen and at least one other environmental allergen~* Dermatographism~* Severe dermatologic condition that may interfere with skin testing~* Pregnancy~* H1 receptor antihistamine taken within 7 days of testing~* Systemic steroids~* Omalizumab taken at any time in the past~* Receiving or received allergen immunotherapy~* Desensitized to any drug within 6 months~* Current uncontrolled or severe asthma~* Eosinophilic esophagitis~* Significant pulmonary, cardiovascular, renal, hepatobiliary, or neurological diseases, or another disease process felt to put a subject at increased risk for adverse events~* Hypersensitivity to any of the inactive ingredients in the allergen extract tablets~* History of mental illness or drug or alcohol abuse that could interfere with the ability to comply with study requirements~* Inability or unwillingness to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- sublingual allergen tablets (Type: EXPERIMENTAL): Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be administered placebo sublingual tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).